Can the South African Covid-19 strain evade vaccines?
Scientists fear new mutation may be less susceptible to existing inoculations

Pressure is mounting on the government to enforce stronger border controls to stem the arrival of the South African Covid strain in the UK, amid fears that vaccinations may not protect against the new variant.
Gene sequencing has so far uncovered 105 cases of the strain in the UK, 11 of which were not linked to patients who had travelled abroad. Matt Hancock told BBC Radio 4’s Today programme that he was “incredibly worried” about the variant.
However, research suggests that three vaccines that are cleared for use do offer at least some defence against the Covid mutation.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
How is it different from other Covid variants?
All viruses mutate as they spread from person to person, but most mutations don’t lead to any substantial changes in the virus. However, the one discovered in South Africa last month had “evolved more than normal”, says The Times. “Even more important, the changes almost all involved the spike protein, improving the virus’s ability to attach to human cells.”
Is it more infectious?
It does seem to be. “Preliminary studies suggest the variant is associated with a higher viral load, which may suggest potential for increased transmissibility,” according to the World Health Organization. The new variant, known as 501.V2, has quickly replaced other mutations in many parts of South Africa, suggesting that it spreads more rapidly than they can.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Is it more deadly?
“At this stage there is no evidence that 501.V2 is associated with higher severity of infection,” says the European Centre for Disease Prevention and Control. Scientists will not be able to give a definitive answer for some time, but hospital admission and mortality rates appear to be similar for all identified variants.
Will the vaccines still work against it?
“Several experts” originally said that vaccines including the Pfizer-BioNTech and Oxford-AstraZeneca jabs may not be able to protect against the new strains, CNBC reported in early January.
But Dr Susan Hopkins of Public Health England has since said that research suggests that three vaccines currently cleared for use provide protection “at a level higher than the minimum standard set by the World Health Organization and the US Food and Drug Administration”, ITV News reports.
“We expect all other vaccines to have a similar level of effectiveness, particularly in reducing hospitalisation and death,” she said.
Trials carried out by Johnson & Johnson showed that its single-shot jab is about 20% to 30% less effective against the South African variant. Further studies are underway.
Holden Frith is The Week’s digital director. He also makes regular appearances on “The Week Unwrapped”, speaking about subjects as diverse as vaccine development and bionic bomb-sniffing locusts. He joined The Week in 2013, spending five years editing the magazine’s website. Before that, he was deputy digital editor at The Sunday Times. He has also been TheTimes.co.uk’s technology editor and the launch editor of Wired magazine’s UK website. Holden has worked in journalism for nearly two decades, having started his professional career while completing an English literature degree at Cambridge University. He followed that with a master’s degree in journalism from Northwestern University in Chicago. A keen photographer, he also writes travel features whenever he gets the chance.
-
Money dysmorphia: why people think they're poorer than they are
In The Spotlight Wealthy people and the young are more likely to have distorted perceptions
By Chas Newkey-Burden, The Week UK
-
Full-body scans: are Neko Health and the like more panic than panacea?
The Explainer Hailed as the 'future of medicine' by some, but not all experts are convinced
By The Week UK
-
The Last of Us, series two: 'post-apocalyptic television at its peak'
The Week Recommends Second instalment of hit show is just as 'gutsy' and 'thoughtful' as the first
By Irenie Forshaw, The Week UK
-
Five years on: How Covid changed everything
Feature We seem to have collectively forgotten Covid’s horrors, but they have completely reshaped politics
By The Week US
-
HMPV is spreading in China but there's no need to worry
The Explainer Respiratory illness is common in winter
By Devika Rao, The Week US
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK